Antipsychotic treatment, in particular with some newer (second-generation) antipsychotic drugs is associated with weight gain and other metabolic side effects. However, the relationship between drug-induced weight gain and dyslipidaemia (abnormal levels of fat in the bloodstream) is not well understood. A Norwegian study of 242 people with severe mental illness compared people taking the second-generation drugs olanzapine and clozapine, people taking other anti-psychotic drugs and people taking no drugs at all. The researchers found no significant differences between the two groups in terms of obesity, high blood pressure and blood-sugar levels but those participants being treated with olanzapine or clozapine had higher levels of 'bad' cholesterol and lower levels of 'good' cholesterol than the other two groups.
Birkenaes, Astrid B. ... [et al] - Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions Journal of Clinical Psychopharmacology April 2008, 28(2), 132-137